Glucagon: difference between revisions
Diff·revision 17 → 18·02:59, 8 Jun 2025
Difference between revision 17 and revision 18 of Glucagon. 4 lines changed; the page grew by 577 bytes.
| Revision 17 — 11:44, 8 May 2025 FreightFenna (talk) reorder the analogues chronologically rather than alphabetically 6,042 bytes +288 | Revision 18 — 02:59, 8 Jun 2025 LedeLeander (talk) correct the dose ladder — the maintenance dose is not the maximum dose 6,619 bytes +577 | ||
|---|---|---|---|
| 43 | Reported weight loss with the triple agonist at the highest doses studied exceeds that reported for GLP-1 monotherapy, though cross-trial comparison of this kind is unreliable and the programmes differ in population, duration and escalation schedule.{{r|coskun2022}} | 43 | Reported weight loss with the triple agonist at the highest doses studied exceeds that reported for GLP-1 monotherapy, though cross-trial comparison of this kind is unreliable and the programmes differ in population, duration and escalation schedule.{{r|coskun2022}} |
| 44 | 44 | ||
| + | 45 | == Formulation and stability == | |
| + | 46 | Glucagon is a notoriously difficult peptide to formulate. At neutral pH it aggregates rapidly into amyloid-like fibrils, so the traditional rescue product was supplied as a lyophilised powder with an acidic diluent for reconstitution immediately before use — an arrangement poorly suited to an emergency.{{r|usp1503}} Non-aqueous and analogue-based ready-to-use formulations have since been introduced. | |
| + | 47 | ||
| 45 | == References == | 48 | == References == |
| 46 | {{reflist}} | 49 | {{reflist}} |
| ⋮ | ⋮ | ||
| 48 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | 51 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> |
| 49 | <ref name="coskun2022">Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." ''Cell Metabolism'' 34(9):1234–1247 (2022). DOI:10.1016/j.cmet.2022.07.013. PMID 35985340.</ref> | 52 | <ref name="coskun2022">Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." ''Cell Metabolism'' 34(9):1234–1247 (2022). DOI:10.1016/j.cmet.2022.07.013. PMID 35985340.</ref> |
| + | 53 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 50 | 54 | ||
| 51 | == See also == | 55 | == See also == |